SYH-2061

N/A

Report date: 2025/11/26 11:12:44
NME

Base Information

Drug NameSYH-2061
Drug Alias NameSYH2061SYH-2061
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsComplement-Mediated DiseasesNephrosisGlomerulonephritis, IGA
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCSPC Pharmaceutical Group LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdCspc Heibei Zhongrun Pharmaceutiacl Co Ltd
Inactive CompaniesN/A
Active IndicationsComplement-Mediated DiseasesNephrosisGlomerulonephritis, IGA
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A